Somatostatin analog therapy for severe polycystic liver disease: Results after 2 years

Nephrology Dialysis Transplantation

Volumn 27, Issue 9, 2012, Pages 3532-3539

  Hogan, Marie C ^a   Masyuk, Tetyana V ^a   Page, Linda ^a   Holmes, David R ^a   Li, Xujian ^a   Bergstralh, Eric J ^a   Irazabal, Maria V ^a   Kim, Bohyun ^a   King, Bernard F ^a   Glockner, James F ^a   Larusso, Nicholas F ^a   Torres, Vicente E ^a  

^a MAYO CLINIC   (United States)

Author keywords

chronic kidney disease; kidney volume; liver cyst; polycystic kidney disease; somatostatin analogs

Indexed keywords

CREATININE; OCTLAR; OCTREOTIDE; PLACEBO; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DEVELOPMENT; KIDNEY POLYCYSTIC DISEASE; LABORATORY TEST; LIVER POLYCYSTIC DISEASE; LIVER WEIGHT; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SAFETY; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; CROSS-OVER STUDIES; CYSTS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HORMONES; HUMANS; KIDNEY DISEASES; LIVER DISEASES; MAGNETIC RESONANCE IMAGING; MALE; PROGNOSIS; QUALITY OF LIFE; RISK FACTORS; SOMATOSTATIN; TIME FACTORS;

EID: 84865773016     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs152     Document Type: Article

References (26)

1. Masyuk TV, Masyuk AI, Torres VE et al. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology 2007; 132: 1104-1116.
2. Hogan MC, Masyuk TV, Page LJ et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010; 21: 1052-1061.
3. Ruggenenti P, Remuzzi A, Ondei P et al. Safety and efficacy of longacting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 2005; 68: 206-216.
4. van Keimpema L, Nevens F, Vanslembrouck R et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009; 137: 1661-1668. e1-2.
5. Caroli A, Antiga L, Cafaro M et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 2010; 5: 783-789.
6. van Keimpema L, de Man RA, Drenth JP. Somatostatin analogues reduce liver volume in polycystic liver disease. Gut 2008; 57: 1338-1339.
7. van Keimpema L, Drenth JP. Effect of octreotide on polycystic liver volume. Liver Int 2010; 30: 633-634.
8. Peces R, Cuesta-Lopez E, Peces C et al. Octreotide reduces hepatic, renal and breast cystic volume in autosomal-dominant polycystic kidney disease. Int Urol Nephrol 2011; 43: 565-569.
9. Ravine D, Gibson RN, Walker RG et al. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 1994; 343: 824-827.
10. Reynolds DM, Falk CT, Li A et al. Identification of a locus for autosomal dominant polycystic liver disease, on chromosome 19p.13.2-13.1. Am J Hum Genet 2000; 67: 1598-1604.
11. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003 (http://ctep.cancer.gov), Publish Date: August 9, 2006.
12. Hanson DP, Robb RA, Aharon S et al. New software toolkits for comprehensive visualization and analysis of three-dimensional multimodal biomedical images. J Digit Imaging 1997; 10: 229-230.
13. Roberts N, Puddephat MJ, McNulty V. The benefit of stereology for quantitative radiology. Br J Radiol 2000; 73: 679-697.
14. Boehm S, Betz H. Somatostatin inhibits excitatory transmission at rat hippocampal synapses via presynaptic receptors. J Neurosci 1997; 17: 4066-4075.
15. Koenig JA, Edwardson JM, Humphrey PPA. Somatostatin receptors in Neuro2A neuroblastoma cells: ligand internalization. Br J Pharmacol 1997; 120: 52-59.
16. Bloch B, Dumartin B, Bernard V. In vivo regulation of intraneuronal trafficking of G protein-coupled receptors for neurotransmitters. Trends Pharmaco Sci 1999; 20: 315-319.
17. Chrispijn M, Drenth JP. Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial. Trials 2011; 12: 246.
18. Schmidt A, Pleiner J, Schaller G et al. Renal hemodynamic effects of somatostatin are not related to inhibition of endogenous insulin release. Kidney Int 2002; 61: 1788-1793.
19. Chapman AB, Bost JE, Torres VE et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2012; 7: 479-486.
20. Burke MT, Gray NA. Carcinoid tumour management in haemodialysis: a case report. Nephrology 2012; 17: 198.
21. Lee P-H, Lin C-L, Lai P-C et al. Octreotide therapy for chylous ascites in a chronic dialysis patient. Nephrology 2005; 10: 344-347.
22. Adabala M, Jhaveri KD, Gitman M. Severe hyperkalaemia resulting from octreotide use in a haemodialysis patient. Nephrol Dial Transplant 2010; 25: 3439-3442.
23. Bigg-Wither GW, Ho KK, Grunstein RR et al. Effects of long term octreotide on gall stone formation and gall bladder function. BMJ 1992; 304: 1611-1612.
24. Davies PH, Stewart SE, Lancranjan L et al. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf) 1998; 48: 311-316.
25. Ho KY, Weissberger AJ, Marbach P et al. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety. Ann Intern Med 1990; 112: 173-181.
26. Hussaini SH, Pereira SP, Veysey MJ et al. Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones. Gut 1996; 38: 775-783.